See All of This Company's Exhibits Find More Exhibits Like This

EX-99.1 2 imgn-20230228xex99d1.htm EX-99.1 ImmunoGen, Inc - Press release of ImmunoGen, Inc. dated March 1, 2023

Graphic

​

ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents

​

ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis

​

Waltham, MA – March 1, 2023 – ImmunoGen, Inc. (Nasdaq: img src='https://www.sec.gov/Archives/edgar/data/855654/000155837023002468/https://www.sec.gov/Archives/edgar/data/855654/000155837023002468/imgn-20230228xex99d1001.jpg' alt="Graphic" style="display:inline-block;height:30.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:158.65pt;">

any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

​

INVESTOR RELATIONS CONTACT

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com

​

MEDIA CONTACTS

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

​

OR

​

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com